cas 54231-35-5|| where to buy 3-Fluoro-2-nitropyridine

Nombre del producto:3-Fluoro-2-nitropyridine

IUPAC Name:3-fluoro-2-nitropyridine

Unidad de embalaje	Stock disponible	Precio($)
CM103502-100g	in stock	Ǒȯȯ
CM103502-500g	in stock	ȖƐȯȯ
CM103502-1000g	in stock	ŪŞƴǫ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 54231-35-5 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :54231-35-5; Fórmula molecular:C5H3FN2O2; Punto de fusión:-; Código de sonrisas:O=[N+](C1=NC=CC=C1F)[O-]; Densidad:

: Número de catálogo:CM103502; Peso molecular:142.09; Punto de ebullición:255.8°C at 760 mmHg; Nº Mdl:MFCD04114127; Almacenamiento:Keep in a tight container and store at 2°C~8°C

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Darovasertib; The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Darovasertib, a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma”. Uveal melanoma (UM) is the most common primary intraocular malignancy. About half of primary uveal melanoma tumors metastasize but with no standard treatment. Most patients with metastatic uveal melanoma have been found to have mutations in GNAQ or GNA11, that are associated with consistent activation of the protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) pathways.
IDEAYA's Darovasertib (IDE196) is a potent, selective small molecule inhibitor of PKC which stops activating PKC/MEK pathway. Darovasertib is under Phase 2 expansion and Phase 3 registrational trial with Crizotinib in GNAQ/11 metastatic cutaneous melanoma.